Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study of Replication Competent Reovirus (Reolysin®) in Combination With GM-CSF in Pediatric Patients With Relapsed or Refractory Brain Tumors

NCT02444546 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT02444546
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02444546 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study of Replication Competent Reovirus (Reolysin®) in Combination With GM-CSF in Pediatric Patients With Relapsed or Refractory Brain Tumors
Lead sponsor
Mayo Clinic
Phase
Phase 1
Overall status
Completed
Start date
June 21, 2015
Completion date
November 21, 2022
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

childhood astrocytoma, childhood atypical teratoid/rhabdoid tumor, diffuse intrinsic pontine glioma, glioma, recurrent childhood anaplastic oligodendroglioma, recurrent childhood brain neoplasm, recurrent childhood glioblastoma, recurrent childhood medulloblastoma, recurrent primitive neuroectodermal tumor, refractory brain neoplasm